Inhaled immune booster shows promise in early safety trial
NCT ID NCT06681402
First seen Apr 19, 2026 · Last updated Jun 14, 2026 · Updated 10 times
Summary
This early-stage trial tested a single dose of an inhaled drug called FLAMOD in 46 healthy adults to see if it is safe and can activate the immune system in the lungs. The goal is to find a dose that could later be used to help prevent or fight pneumonia. No treatment benefit was expected for participants, as the study focused only on safety and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier régional universitaire de de Tours
Tours, 37044, France
Conditions
Explore the condition pages connected to this study.